Article in eLife, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Nikol Kadeřábková *Department of Molecular Biosciences, The University of Texas at Austin, Austin, United States.ORCID 0000-0002-1205-1644
R Christopher D Furniss *Centre for Bacterial Resistance Biology, Department of Life Sciences, Imperial College London, London, United Kingdom.
Evgenia MaslovaDivision of Biosciences, Department of Life Sciences, College of Health and Life Sciences, Brunel University London, Uxbridge, United Kingdom.
Kathryn E PotterDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, United States.
Lara EisaiankhongiDivision of Biosciences, Department of Life Sciences, College of Health and Life Sciences, Brunel University London, Uxbridge, United Kingdom.
Patricia BernalDepartamento de Microbiología, Facultad de Biología, Universidad de Sevilla, Seville, Spain.ORCID 0000-0002-6228-0496
Alain FillouxCentre for Bacterial Resistance Biology, Department of Life Sciences, Imperial College London, London, United Kingdom.ORCID 0000-0003-1307-0289
Cristina LandetaDepartment of Biology, Indiana University, Bloomington, United States.ORCID 0000-0003-4065-9646
Diego GonzalezLaboratoire de Microbiologie, Institut de Biologie, Université de Neuchâtel, Neuchâtel, Switzerland.
Ronan R McCarthyDivision of Biosciences, Department of Life Sciences, College of Health and Life Sciences, Brunel University London, Uxbridge, United Kingdom.
Despoina A I MavridouDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, United States.ORCID 0000-0002-7449-1151
Funding
The interplay between cell envelope protein homeostasis and antibiotic resistance in Gram-negative bacteriaR01AI158753 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI Despoina Mavridou · 2022 to 2026
$1.9M
Academy of Medical Sciences SBF006\1040Biotechnology and Biological Sciences Research Council BB/M011178/1Biotechnology and Biological Sciences Research Council BB/V007823/1British Heart Foundation SBF006\1040Cystic Fibrosis Foundation 004846I222Diabetes UK SBF006\1040MCIN/AEI/10.13039/501100011033 Spanish agency PID2021-123000OB-I00MCIN/AEI/10.13039/501100011033 Spanish agency RYC2019-026551-IMedical Research Council MR/M009505/1Medical Research Council MR/Y001354/1National Centre for the Replacement Refinement and Reduction of Animals in Research NC/V001582/1NIH HHS R01AI158753Portugal Extra Exploratory Project 2022.15740.UTASwiss National Science Foundation PZ00P3_180142Texas Biologics TXB-24-02The Government Department of Business, Energy and Industrial Strategy SBF006\1040Welch Foundation F-2250-20250403Wellcome Trust SBF006\1040
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Antibiotic potentiation and inhibition of cross-resistance in pathogens associated with cystic fibrosis. · full record | OpenQuestion